144 related articles for article (PubMed ID: 37984956)
1. Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following
Wang C; Dong Q; Liu X; Ni M; Xie Q; Xiao J; Tao T
BMJ Open; 2023 Nov; 13(11):e073983. PubMed ID: 37984956
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
3.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
4. Detection of prostate cancer with
Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
[TBL] [Abstract][Full Text] [Related]
5. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
Bodar YJL; Boevé LMS; van Leeuwen PJ; Baars PC; Nieuwenhuijzen JA; van Haarst EP; Oddens JR; Donswijk ML; van Riel LAMJG; Scheltema MJ; Meijer D; Hendrikse NH; Oprea-Lager DE; Vis AN
BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
[TBL] [Abstract][Full Text] [Related]
6. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
7. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
[TBL] [Abstract][Full Text] [Related]
8. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
10. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial.
Krausewitz P; Bundschuh RA; Gaertner FC; Essler M; Attenberger U; Luetkens J; Kristiansen G; Muders M; Ohlmann CH; Hauser S; Ellinger J; Ritter M
Trials; 2023 Mar; 24(1):167. PubMed ID: 36879271
[TBL] [Abstract][Full Text] [Related]
13. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
15. Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy?
Tang W; Tang Y; Qi L; Zhang Y; Tang G; Gao X; Hu S; Cai Y
J Urol; 2023 Dec; 210(6):845-855. PubMed ID: 37647549
[TBL] [Abstract][Full Text] [Related]
16. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
18. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
Heetman JG; Lavalaye J; Polm PD; Soeterik TFW; Wever L; Paulino Pereira LJ; van der Hoeven EJRJ; van Melick HHE; van den Bergh RCN
Eur Urol Oncol; 2024 Apr; 7(2):204-210. PubMed ID: 37296065
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Hope TA; Eiber M; Armstrong WR; Juarez R; Murthy V; Lawhn-Heath C; Behr SC; Zhang L; Barbato F; Ceci F; Farolfi A; Schwarzenböck SM; Unterrainer M; Zacho HD; Nguyen HG; Cooperberg MR; Carroll PR; Reiter RE; Holden S; Herrmann K; Zhu S; Fendler WP; Czernin J; Calais J
JAMA Oncol; 2021 Nov; 7(11):1635-1642. PubMed ID: 34529005
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]